LLY
Eli Lilly and Company
LLY has the edge over LUNG overall, supported by lower modeled downside and stronger fundamentals.
LUNG
Pulmonx Corporation
LUNG's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LUNG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
LUNG's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LUNG PE Valuation
LUNG has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LUNG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect LUNG's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LUNG on earnings quality, reporting a profit while its opponent remains loss making.
LUNG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.01 | +$0.40 |
| Q2 2026 | -$1.16 | +$0.27 |
| Q1 2026 | -$1.30 | +$0.14 |
| Q4 2025 | -$1.33 | +$0.11 |
| Q3 2025 | -$1.41 | +$0.06 |
| Q2 2025 | -$1.43 | +$0.07 |
| Q1 2025 | -$1.44 | +$0.10 |
| Q4 2024 | -$1.44 | +$0.16 |
LUNG is still losing money, but far less than before: $1.01 per share over the past year, against $2.32 at its worst in mid-2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LUNG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LUNG on profitability, with a higher operating margin.
LUNG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.8M | +6.2% |
| Q2 2026 | $22.8M | -4.6% |
| Q1 2026 | $20.6M | -8.7% |
| Q4 2025 | $22.6M | -4.9% |
| Q3 2025 | $21.5M | +5.5% |
| Q2 2025 | $23.9M | +15% |
| Q1 2025 | $22.5M | +20% |
| Q4 2024 | $23.8M | +23% |
LUNG's revenue grew through 2024 and has held roughly level since: $23M last quarter, up 6.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -33% | +34 points |
| Q2 2026 | -40% | +22 points |
| Q1 2026 | -63% | +1.7 points |
| Q4 2025 | -44% | +13 points |
| Q3 2025 | -67% | +2.4 points |
| Q2 2025 | -62% | +13 points |
| Q1 2025 | -65% | +13 points |
| Q4 2024 | -56% | +16 points |
LUNG's operating margin was −33% last quarter, up 34 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LUNG on cash generation, producing positive trailing cash flow while its opponent burns cash.
LUNG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.2M | +$5.1M |
| Q2 2026 | -$5.2M | -$1.3M |
| Q1 2026 | -$10.1M | +$3.4M |
| Q4 2025 | -$7.1M | -$256K |
| Q3 2025 | -$8.3M | -$593K |
| Q2 2025 | -$4M | +$2.3M |
| Q1 2025 | -$13.5M | -$1.3M |
| Q4 2024 | -$6.8M | +$1.8M |
LUNG has burned cash in almost every quarter: −$26M over the past year, against −$33M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LUNG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LUNG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +708K shares |
| 1 year | +5.5% | +2.2M shares |
| 3 years | +13% | +5.1M shares |
| 5 years | +18% | +6.7M shares |
LUNG has 43M diluted shares, up 5.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | $27,000 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | $26,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LUNG Net Leverage
LUNG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LUNG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.3 | Neutral |
| Stochastic | 76.2 | Neutral |
LUNG's weekly RSI is 64 (neutral) and its Stochastic is 76 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LUNG PE vs Healthcare Sector
LUNG has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LUNG on trend strength, trading above more of its moving averages.
LUNG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.22 | 35% above |
| 20 week MA | $2.01 | 49% above |
| 50 week MA | $1.79 | 68% above |
| 100 week MA | $2.87 | 4.5% above |
| 200 week MA | $6.30 | 52% below |
LUNG has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 52% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
LUNG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.9 | $65.2 | +56% |
| 2021 | $65.2 | $33.0 | -49% |
| 2022 | $33.0 | $7.85 | -76% |
| 2023 | $7.85 | $12.8 | +62% |
| 2024 | $12.8 | $6.70 | -47% |
| 2025 | $6.70 | $2.22 | -67% |
| 2026 YTD | $2.22 | $3.00 | +35% |
LUNG has the edge over LLY on returns for 2026, with the stronger performance.